The following content is for educational purposes only, is intended for healthcare professionals, and does not supercede local clinical guidelines.
This page provides links to CaReMe UK guidelines and publications and to other relevant resources for healthcare practitioners involved in the care of patients with cardio-renal-metabolic disorders.
CaReMe UK guidance documents
Guide for non-diabetes specialist physicians and primary care teams for cardiovascular risk optimisation in patients with Type 2 diabetes and atherosclerotic cardiovascular disease. Published 2020: https://abcd.care/resource/careme-guidance-cvd-and-primary-care-physicians
CaReMe UK Publications
- Guidelines in practice: Use a Combined Cardio–Renal–Metabolic Approach to Treat Cardiovascular Disease in Patients With Kidney Disease or Diabetes: https://www.medscape.co.uk/viewarticle/use-combined-cardio-renal-metabolic-approach-treat-2022a10029f1
- Rapid Response to: Rapid response to: SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline: https://www.bmj.com/content/373/bmj.n1091/rr
- Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently: https://link.springer.com/article/10.1007/s13300-022-01242-y
- Guidelines in Practice: Manage Diabetes and Comorbidities with a Joined-Up Strategy: https://www.medscape.co.uk/viewarticle/manage-diabetes-and-comorbidities-joined-strategy-2022a10017xk
- Guidelines in Practice: Patient Scenarios: CaReMeUK Guidance on the Management of Diabetes and Comorbidities: https://www.medscape.co.uk/viewarticle/patient-scenarios-caremeuk-guidance-management-diabetes-and-2023a10002qu
CaReMe Webinars
This webinar was held live on Monday 22 September, from 6:30pm – 8pm.
It was chaired by Prof André Ng and Prof Stephen Wheatcroft and featured three presentations:
- Weight loss drugs in cardiology – what is the evidence and what should we be doing? Prof Chim Lang
- Heart failure in people with type 1 diabetes – when can SGLT2 inhibitors and GLP-1 receptor agonists be used? Dr Iffy Mordi
- Between a rock and a hard place – how to manage hyperkalaemia in patients who need RAAS inhibition. Dr Andrew Frankel
The event concluded with a live Q&A with the faculty.
The full 90-minute webinar was recorded and is available to watch on the BCS Digital Knowledge Hub.
Other resources
Overcoming hyperkalaemia as a barrier to achieving optimal RAASi therapy and cardiorenal protection in individuals with cardiorenal disease
These resources are intended to be used by healthcare providers in the management of hyperkalaemia in patients with cardiorenal disease receiving renin-angiotensin-aldosterone system inhibitors (RAASi). They were developed by a multi-disciplinary panel of experts, comprising cardiologists, nephrologists, general practitioners, and specialist nurses, organised and funded by AstraZeneca. Healthcare practitioners may use these utilities to assist the development of their own local solutions to issues related to RAAS optimisation.
Listen to our recent podcast episode created by the expert group here:
- Practical guide to RAASi* optimisation in individuals with cardiorenal disease
- Practical guide to the definition and management of acute hyperkalaemia in individuals with cardiorenal disease on RAASi* therapy
- Example hospital discharge summary for an individual with cardiorenal disease on RAASi* therapy with hyperkalaemia
- Long-term monitoring advice sheet for individuals with cardiorenal disease on RAASi* therapy with hyperkalaemia
- Cardiorenal disease, RAASi* therapy and hyperkalaemia – what does it mean to me?
- Questions to ask your healthcare professional: cardiorenal disease, RAASi* therapy and hyperkalaemia
These utilities were developed by a steering group of cardiorenal experts, organised and funded by AstraZeneca: Andrew H. Frankel1, Kate Bramham2, Barbara Byrne3, Geraldine Chiu4, Ruby Chumber5, Sarah Jane Davies6, Ahmet Fuat7, Laura Gray4, Darren Green8, William Priestman9, Mandie Welch10, Simon G. Williams11, Stephen Wheatcroft12
1Imperial College Healthcare NHS Trust, London, UK; 2King’s College London and King’s College Hospital NHS Foundation Trust, London, UK; 3Ealing Community Heart Failure Service Imperial College Healthcare NHS Trust, London, UK; 4AstraZeneca UK Limited, London, UK; 5Nottingham University Hospitals NHS Trust, Nottingham, UK; 6Woodlands Medical Centre, Cardiff, UK; 7Orchard Court Surgery, Darlington, UK; 8Northern Care Alliance NHS Foundation Trust, Salford, UK and University of Manchester, Manchester, UK; 9Heath Lane Surgery, Earl Shilton, UK; 10Cwm Taf Morgannwg University Health Board, Royal Glamorgan Hospital, BSH Nurse Forum Committee Member, and Wales NHS Collaborative, Abercynon, UK; 11Wythenshawe Hospital, Manchester NHS Foundation Trust and University of Manchester, Manchester, UK; 12University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, UK
CardioVascular Residual Risk Reduction (CVR3) – Pillars of Care Guideline & Pathway
This one-page guideline was created by a multi-disciplinary team in West Yorkshire. Intended for use in people with known atherosclerotic disease, it brings together key aspects of managing lipids, metabolic risk and thrombotic risk and is suitable for use as a quick reference guide in primary or secondary care
https://britishcardiovascularsociety.org.uk/wp-content/uploads/2026/05/CVR3-v8_30.04.26.pdf
[Author: Dr Waqas Tahir (GPwER Diabetes and CVRM), Co-authors: Professor Stephen Wheatcroft (Cardiology), Dr Rani Khatib (Cardiology) & Mr Marc Bailey (Vascular Medicine)]
Cardiovascular Kidney Metabolic (CVKM) Toolkit: Secondary Care Settings
This toolkit, developed by a subgroup of NHS England’s Renal and Cardiac Clinical Reference Groups, provides a framework to support the development of location agnostic, specialty led cardiovascular kidney metabolic (CVKM) services in acute care settings. The toolkit is published on NHS Futures (Renal Transformation pages) to support shared learning and ongoing access.
https://britishcardiovascularsociety.org.uk/wp-content/uploads/2026/05/CVKM-TOOL-KIT-MAY-2026.pdf